The biochemical pathways and metabolic requirements that enable tumor survival and growth may be used to design targeted cancer therapies.
A protein thought to fuel pancreatic cancer development plays a much more complicated role, a new study finds. PDX1 is critical for cancer growth, but blocking it may lead to more aggressive tumors.
The University of Michigan Comprehensive Cancer Center is one of 12 sites to join Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
A new analysis projects that pancreatic cancer will be the second-leading cause of cancer death in the United States by 2030, behind lung cancer.